University of Dundee

‘An emergent cancer pathway protecting genome integrity’

Event Date: 
Thursday, June 18, 2020 - 12:00
Event Location: 
School of Life Sciences, MSI Small Lecture Theatre
Host: 
Dr Gopal Sapkota
Event Speaker: 
Dr Peter Parker
Institution: 
The Francis Crick Institute
Event Type: 
Seminar
Share
 
MRC Protein Phosphorylation and Ubiquitylation Special Alumnus Seminar
 

Peter Parker read Biochemistry (BA) at Oxford and received his PhD in Clinical Biochemistry at Oxford under the supervision of Professor Sir Philip Randle. He subsequently gained an MRC Post-Doctoral Fellowship to work with Professor Sir Philip Cohen in Dundee from 1980-1983, where he made important contributions to the understanding of how insulin and adrenalin control glycogen synthesis. He started working in the field of oncology when he joined Professor Mike Waterfield’s team in London, subsequently moving as a founder member to the Ludwig Institute at UCL. In 1990, he was appointed Principal Scientist at ICRF which evolved to become the London Research Institute (LRI) in 2002. Peter moved with the LRI into the newly founded Francis Crick Institute in 2015 as a Senior Group Leader. Peter has held a joint appointment with King’s College London since 2006 where he was Head of Cancer Research until 2017; he is currently Director of the Cancer Research UK King’s Health Partners Centre at KCL and Executive member of the City of London Cancer Centre.

 

Peter Parker was elected to the European Molecular Biology Organisation in 1997, to the Academy of Medical Sciences in 2000. He was awarded the Morton Prize Lecture of the Biochemical Society in 2004, elected a Fellow of the Royal Society in 2006 and elected to the European Academy of Cancer Sciences in 2011.

 

Peter Parker has run a cancer research group since 1986 publishing over 350 primary research articles and reviews in the area of signal transduction, biomarkers and cancer. He was a co-founder of the company PIramed, which developed the first really potent and specific inhibitors of Class 1 PI 3-kinases, and was acquired by Genentech for $US 175 million in 2008. By founding and working with this and other companies (Symansis, FASTBASE Solutions) he has pursued translational interests in the areas of cancer drug development and biomarkers. Peter championed and chaired the CRUK TRICC committee (now evolved to EMERP) seeking to develop the application of Biomarkers in clinical trials, returning to serve on EMERP until 2018. He currently serves on the CRUK Innovation Prize committee and Chairs the SAB for TDL (CRUK), MPL (Vienna), as well as serving on a number of other advisory boards (including Babraham and Beatson Institutes, and commercial ventures).